TITLE

PLURISTEM COMPLETES DOSING FOR FIRST PATIENTS IN CLI TRIAL

PUB. DATE
January 2010
SOURCE
Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the completion by Pluristem Therapeutics Inc. of dosing of the first of three dosage groups of patients in Europe as part of its Phase I dose-escalating clinical trial of its placenta-derived cell therapy product PLX-PAD, for the treatment of critical limb ischemia (CLI). The first dose group were given the lowest dose level. According to Andre Schmidt-Lucke, director of the Franziskus-Krankenhaus Institute of Berlin, positive initial results would enable them to move into intermediate dose level.
ACCESSION #
47191580

 

Related Articles

  • PLURISTEM GETS INTERIM TOP-LINE RESULTS FROM PLX-PAD TRIALS.  // Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3 

    The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment,...

  • Clinic Roundup.  // BioWorld Today;11/4/2011, Vol. 22 Issue 215, p8 

    The article reports on clinical studies done by biotechnology companies as of November 4, 2011. Avanir Pharmaceuticals of Aliso Viejo, California started the Phase II trial on the use of AVP-923 for treatment of central neuropathic pain. Results of the first clinical study of Bellicum...

  • PLURISTEM GETS DSMB APPROVAL FOR PLX-PAD FINAL DOSE LEVEL.  // Biotech Business;Apr2010, Vol. 23 Issue 4, p6 

    The article announces the approval received by Pluristem Therapeutics Inc. of Haifa, Israel from the Safety Monitoring Board to advance to the highest and final dose level with its placenta-derived cell therapy (PLX-PAD) trial in Europe for the treatment of critical limb ischemia (CLI). Dr. Hans...

  • Financings Roundup.  // BioWorld Today;9/24/2008, Vol. 19 Issue 186, p5 

    The article reports that Pluristem Therapeutics Inc. of New York City has raised additional fundings of $1 million in September 2008. These new fundings will be used to support the development of their preclinical allogenic, placenta-derived cell therapy products. As reported, Pluristem sold...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld International;5/5/2010, Vol. 15 Issue 18, p5 

    The article deals with the preliminary Phase I data released by Pluristem Therapeutics Inc. for its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia in May 2010. Information on the Phase I trial results is presented. It discloses the company's negotiations for a Phase II...

  • FDA Clinical Hold on PLX Safety Study Trips Pluristem. Powers, Marie // BioWorld Today;6/5/2013, Vol. 24 Issue 107, p1 

    The article reports on the 14.4% decrease in stocks of Pluristem Therapeutics Inc. amid the decision of the U.S. Food and Drug Administration (FDA) to stop the U.S. Phase II study of its Placental expanded cell therapy. Zami Aberman, chairman and chief executive officer of the biotechnology...

  • Pluristem files IND application to begin Phase I critical limb ischemia trial.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p10 

    The article reports on the investigational drug application filed by Pluristem Therapeutics to the U.S. Food and Drug Administration (FDA) in its aim to commence clinical trial with its placental-derived stromal cell product for the treatment of critical limb ischemia. The firm will begin its...

  • Cell Therapy Treatment for Critical Limb Ischemia. Prather, William R. // Drug Discovery & Development;Nov/Dec2009, Vol. 12 Issue 10, p40 

    The article discusses the treatment of the peripheral artery disease (PAD) critical limb ischemia (CLI) through cell therapy. It is stated that clinical trials are conducted by Pluristem Therapeutics Inc. in the U.S. and Europe to identify the effectiveness of adherent stromal cell (ASC) in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics